QR kód

Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With Immunotherapy

Introduction: The predictive and prognostic implications of different KRAS mutation (KRASm) subtypes in metastatic NSCLC have not been clearly defined. We used a nationwide observational database to investigate whether KRASm subtypes differ in their association with survival in metastatic NSCLC trea...

Celý popis

Uloženo v:
Hlavní autoři: Lova Sun, MD, MSCE, Yunyun Zhou, PhD, Elizabeth A. Handorf, PhD, Hossein Borghaei, DO, Jessica Bauman, MD, Charu Aggarwal, MD
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2025-01-01
Edice:JTO Clinical and Research Reports
Témata:
NSCLC
Immunotherapy
KRAS mutation
On-line přístup:http://www.sciencedirect.com/science/article/pii/S2666364324001255
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky